Miguel J, Araujo LH, Costa R. Cost-effectiveness of erlotinib compared to gefitinib for NSCLC with EGFR mutations at the Inca. JBES [Internet]. 2020 Apr. 20 [cited 2025 Nov. 23];12(1):8-15. Available from: https://www.jbes.com.br/index.php/jbes/article/view/171